How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,190 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy. (Abstract)

The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy. To determine how often prostate- and bladder-specific medications for lower urinary tract symptoms are used following a transurethral prostatectomy (TURP).This study utilized several linked, routinely collected datasets from the province of Ontario, Canada to identify men older than 66 years who underwent their first TURP between April 2003 and March 2016. The primary outcome (...) was the probability of using at least 30 days of either prostate-specific alpha blockers (AB), 5-alpha reductase inhibitors (5ARI), or anticholinergics/beta-3 agonists (AC/B3) after their TURP.We identified 58,038 men (median age 75), with a median follow-up of 4.9 years. In the 6 months prior to their TURP, AB, 5ARIs or AC/B3 were used by 62%, 32%, and 6%, respectively. Following a 90-day washout period after TURP, these medications were used by 27%, 20%, and 15% of men, respectively. The cumulative probability

2019 Urology

182. Alpha-blocker and risk of dementia in patients with benign prostate hyperplasia: A nationwide population-based study using the National Health Insurance Service database. (Abstract)

Alpha-blocker and risk of dementia in patients with benign prostate hyperplasia: A nationwide population-based study using the National Health Insurance Service database. A recent study demonstrated that use of tamsulosin increased the risk of dementia in benign prostate hyperplasia patients. However, this study had a number of limitations. We evaluated the association between alpha-blockers and dementia in patients with benign prostate hyperplasia.From the National Health Insurance Service (...) database, we collected and analyzed data pertaining to alpha-blockers and dementia in the entire Korean adult population with benign prostate hyperplasia between January 2011 and December 2011. These patients were followed up until September 2017. We tested the effect of alpha-blockers on the risk of dementia using propensity score-matched Cox proportional hazard regression models and Kaplan-Meier survival analysis.During a mean follow-up period of 1,580 (± 674.3) days, all inclusion and exclusion

2019 Journal of Urology

183. Potential Therapeutic Effects of Underground Parts of <i>Kalanchoe gastonis-bonnieri</i> on Benign Prostatic Hyperplasia. (Full text)

Potential Therapeutic Effects of Underground Parts of Kalanchoe gastonis-bonnieri on Benign Prostatic Hyperplasia. Benign Prostatic Hyperplasia (BPH) affects mainly older men. It is estimated to affect 50% of 51-60-year-old men and 70% of 61-70-year-old men. BPH is a nonmalignant proliferation of epithelial and stromal cells of the prostate gland regions. Despite the use of conventional pharmacological therapy, herbal medicines are used in BPH therapy, and several mechanisms of action (...) have been suggested based on their complex chemical composition. Considering the ethnomedicinal uses of Kalanchoe gastonis-bonnieri (KGB), we evaluated the inhibitory effects on the proliferation of stromal cells from primary benign prostatic hyperplasia (BPH) of four different aqueous extracts from this plant: underground parts from specimens in flower (T1 treatment), leaves from specimens in flower (T2 treatment), and flowers (T3 treatment) and leaves from specimens not in flower (T4 treatment

2019 Evidence-based Complementary and Alternative Medicine (eCAM) PubMed abstract

184. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms (Abstract)

A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms To evaluate the efficacy and safety of combination therapy comprising a short-acting anticholinergic, imidafenacin and an alpha-blocker compared with monotherapy with an alpha-blocker only in men with lower urinary tract symptoms (LUTS) and storage symptoms.The 12-week (...) , prospective, double-blind, randomised trial enrolled men with LUTS and storage symptom. The inclusion criteria were a total International Prostate Symptom Score (IPSS) ≥12, an IPSS question 4 score ≥2, ≥8 micturitions in 24 hours, and a prostate volume >20 mL. The primary outcome was a change in the micturition number from baseline. Bladder diary variables, Patient Perception of Intensity of Urgency Scale (PPIUS) scores, IPSS and safety were assessed.Of 260 patients screened, 221 completed the study

2017 EvidenceUpdates

185. Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. (Full text)

Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. To assess the efficacy and safety of green-light laser photoselective vaporisation of the prostate (PVP) compared with transurethral resection of the prostate (TURP) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH (...) ).Systematic review and meta-analysis, conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.PubMed, EMBASE, the Cochrane Library until October 2018.Randomised controlled trials and prospective studies comparing the safety and efficacy of PVP versus TURP for LUTS manifesting through BPH.Perioperative parameters, complications rates and functional outcomes including treatment-related adverse events such as International Prostate Symptom Score (IPSS

2019 BMJ open PubMed abstract

186. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. (Abstract)

The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Benign prostate hyperplasia (BPH) is one of the most common urologic diseases. However, the molecular and cellular mechanisms involving the stromal and epithelial components of the prostate that lead to BPH remain unclear.To review and evaluate the evidence implicating microRNAs (miRNAs) in the pathogenesis of BPH.A systematic search of the PubMed and Embase databases (...) be lastly investigated as possible therapy of one of the most common urologic diseases among elderly men. PATIENT SUMMARY: miR-221 has the potential to be used both as a biomarker and novel target in the early diagnosis and therapy of benign prostate hyperplasia. The development of new pharmacologic therapies enabling the synthesis of anti-miR-221 should be lastly investigated as a possible therapy of one of the most common urologic diseases among elderly men.Copyright © 2018 European Association

2018 European urology focus

187. The effects of statins on benign prostatic hyperplasia and the lower urinary tract symptoms: A Meta-analysis. (Full text)

The effects of statins on benign prostatic hyperplasia and the lower urinary tract symptoms: A Meta-analysis. The aim of this meta-analysis was to understand the relationship between statin with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).A systematic literature search was conducted using PubMed, Embase, Cochrane Library, Chinese Medical and Biological Literature Database, China HowNet, Vip, and Wanfang. We calculated pooled odds ratios (OR) and 95% CI

2019 Medicine PubMed abstract

188. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. (Full text)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year.Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane (...) Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The data was evaluated and statistically analyzed by using RevMan version 5.3.0.Five studies including 4348 patients were studied. The analysis found that the combination group was significantly greater effect in international prostate symptom score (mean difference [MD], - 1.43; 95% confidence interval [CI], - 2.20 to - 0.66; P = 0.0003), prostate volume (MD

2019 BMC Urology PubMed abstract

189. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. (Abstract)

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. To assess the effects of phosphodiesterase inhibitors (PDEI) compared to placebo and other standard of care drugs i.e alpha blockers (AB) and 5-alpha reductase inhibitors (5-ARI) in men with LUTS consistent with benign prostatic hyperplasia (BPH).We conducted a systematic search of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Web of Science, and clinical (...) and extracted data. Primary outcomes were effects on urinary symptoms as assessed by the International Prostate Symptom Score (IPSS-total; score ranging from 0 to 35, with higher values reflecting more symptoms), urinary bother as assessed by the Benign Prostatic Hyperplasia Impact Index (BPHII; score ranging from 0 to 13, with higher values reflecting more bother), and adverse events (AE). We used GRADE to rate the quality of evidence. We considered short-term (up to 12 weeks) and long-term (12 weeks

2019 BJU international

190. Herbal medicine for benign prostatic hyperplasia: A protocol for a systematic review of controlled trials. (Full text)

Herbal medicine for benign prostatic hyperplasia: A protocol for a systematic review of controlled trials. Herbal medicine has been used to manage benign prostatic hyperplasia (BPH) and the associated lower urinary tract symptoms, but its effects are not yet fully understood. The purpose of this review is to assess the efficacy and safety of herbal medicine as a treatment for BPH.Thirteen databases will be searched for relevant studies from inception to the present date. We will include

2019 Medicine PubMed abstract

191. [Transurethral bipolar plasmakinetic prostatectomy for benign prostatic hyperplasia in high-risk and senior patients in China: a systematic review and meta-analysis]. (Abstract)

[Transurethral bipolar plasmakinetic prostatectomy for benign prostatic hyperplasia in high-risk and senior patients in China: a systematic review and meta-analysis]. Objective: To evaluate the effectiveness and safety of transurethral bipolar plasmakinetic prostatectomy in the treatment of benign prostatic hyperplasia in high-risk and senior patients in China. Methods: The PubMed, Cochrane Library, CBM, CNKI and WanFang databases were searched with computer for collecting relevant (...) --174.01), -76.10 ml (95%CI: -116.71--35.50), -159.90 ml(95%CI: -207.21--112.59) and -87.70 ml (95%CI: -91.91--83.48). The event rate of postoperative adverse reactions all were not high. Conclusion: Transurethral bipolar plasmakinetic prostatectomy has better clinical efficacy and no obvious side effects in the treatment of benign prostatic hyperplasia in high-risk and senior patients in China.

2019 Zhonghua yi xue za zhi

192. Can surgical treatment for benign prostatic hyperplasia improve sexual function? A systematic review. (Abstract)

Can surgical treatment for benign prostatic hyperplasia improve sexual function? A systematic review. Erectile dysfunction is an established, well known risk of any operative management of benign prostatic hyperplasia (BPH). However, there are some cases reported in which surgical treatment has paradoxically improved erectile function. Here, we present a systematic review of the literature pertaining to the effect of surgery on sexual function, focusing on reports of improvement in erectile (...) function following surgery.We searched PUBMED, EMBASE, Web of Knowledge, and SCOPUS databases for the following keywords: (("sexual function" OR "erectile function") AND "improvement" AND "benign prostatic hyperplasia" AND "surgery").Sixteen studies (total n = 2087) were reviewed which reported a significant improvement in any aspect of erectile function. Ten of these studies had a follow-up period of 12 months or more while five had a follow up less than 12 months. Various surgical methods were

2019 The aging male : the official journal of the International Society for the Study of the Aging Male

193. Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature. (Full text)

Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature. To evaluate the effect of oral desmopressin in patients with nocturia associated with benign prostatic hyperplasia (BPH).With a rise of the use of oral desmopressin in the treatment of nocturia in patients with BPH, a systematic review was performed according to the Cochrane systematic reviews guidelines and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta (...) and beneficial for improving the International Prostate Symptom Score and nocturnal symptoms. All patients should be educated about the mechanism of desmopressin action to avoid treatment discontinuation due to adverse events.

2019 Arab journal of urology PubMed abstract

194. Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population. (Full text)

Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population. This study aimed to investigate the metabolic syndrome-related risk factors for the development of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) in healthy men.A total of 4880 healthy men who underwent transrectal ultrasonography at our hospital during routine health examinations were included in this study. Those who (...) had undergone a prior biopsy or surgery for prostate disease, were suspected of having urinary tract infection, or were taking BPH/LUTS or metabolic syndrome medications were excluded. BPH/LUTS was defined as an International Prostate Symptom Score (IPSS) of ≥8 and a prostate volume (PV) of ≥30 cm.The subjects had a mean age of 54.1 years, PV of 29.2 cm, prostate-specific antigen (PSA) level of 1.20 ng/mL, and IPSS of 9.2. The annual PV growth rate was 0.48 cm/year. Age, body mass index (BMI), PSA

2019 Medicine PubMed abstract

195. Efficacy and safety of HT080 for lower urinary tract symptoms associated with benign prostatic hyperplasia: A study protocol for a randomized, double-blind, placebo-controlled trial. (Full text)

Efficacy and safety of HT080 for lower urinary tract symptoms associated with benign prostatic hyperplasia: A study protocol for a randomized, double-blind, placebo-controlled trial. Lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) are one of the most common conditions seen in middle-aged and elderly men and threaten their quality of life. Since conventional pharmacotherapy for LUTS/BPH can lead to sexual side effects, herbal therapies are widely used (...) of 100 eligible men aged 40 to 75 years with an International Prostate Symptom Score of 8 to 19 will be randomized in a 1:1 ratio and receive either HT080 (500 mg) or placebo twice a day for 12 weeks. All participants will be evaluated for efficacy and safety at baseline and weeks 6 and 12. The primary endpoint is the change in International Prostate Symptom Score between baseline and week 12. The secondary efficacy variables are uroflowmetry parameters (maximal urinary flow rate and post-void

2019 Medicine PubMed abstract

196. Re: New Treatment Strategies for Benign Prostatic Hyperplasia in the Frail Elderly Population: A Systematic Review. (Abstract)

Re: New Treatment Strategies for Benign Prostatic Hyperplasia in the Frail Elderly Population: A Systematic Review. 29677858 2019 05 07 2019 05 07 1527-3792 199 5 2018 05 The Journal of urology J. Urol. Re: New Treatment Strategies for Benign Prostatic Hyperplasia in the Frail Elderly Population: A Systematic Review. 1088-1091 S0022-5347(18)30243-X 10.1016/j.juro.2018.02.041 Griebling Tomas L TL eng Journal Article Comment 2018 02 19 United States J Urol 0376374 0022-5347 AIM IM Minerva Urol (...) Nefrol. 2017 Apr;69(2):119-132 27681493 Aged Frail Elderly Humans Male Prostatic Hyperplasia 2018 02 12 2018 4 22 6 0 2018 4 22 6 0 2019 5 8 6 0 ppublish 29677858 S0022-5347(18)30243-X 10.1016/j.juro.2018.02.041

2019 The Journal of urology

197. Photoselective Vaporization for the Treatment of Benign Prostatic Hyperplasia

Photoselective Vaporization for the Treatment of Benign Prostatic Hyperplasia PVP for Treatment of Benign Prostatic Hyperplasia: OHTAC Recommendation. August 2013; pp. 1–7 1 Photoselective Vaporization for the Treatment of Benign Prostatic Hyperplasia Ontario Health Technology Advisory Committee August 2013 PVP for Treatment of Benign Prostatic Hyperplasia: OHTAC Recommendation. August 2013; pp. 1–7 2 Background As an alternative to transurethral resection of the prostate (TURP), photoselective (...) vaporization of the prostate (PVP) provides a bloodless, relatively painless relief of lower urinary tract symptoms (LUTS) for men with benign prostatic hyperplasia (BPH). Following a review of the evidence on energy delivery systems for treatment of benign prostatic hyperplasia in 2006, the Ontario Health Technology Advisory Committee (OHTAC) recommended that a study be conducted to evaluate PVP in Ontario. A field evaluation * (http://www.hqontario.ca/en/documents/eds/2013/full-report-PVP.pdf

2013 Health Quality Ontario

198. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety

Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo

2014 Health Technology Assessment (HTA) Database.

199. OHTAC recommendation: Photoselective vaporization for the treatment of benign prostatic hyperplasia

OHTAC recommendation: Photoselective vaporization for the treatment of benign prostatic hyperplasia OHTAC recommendation: photoselective vaporization for the treatment of benign prostatic hyperplasia OHTAC recommendation: photoselective vaporization for the treatment of benign prostatic hyperplasia Ontario Health Technology Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Ontario Health Technology Advisory Committee. OHTAC recommendation: photoselective vaporization for the treatment of benign prostatic hyperplasia. Toronto: Health Quality Ontario (HQO). OHTAC recommendation. 2013 Authors' conclusions Based on the earlier analysis from the Medical Advisory Secretariat on "Energy Delivery Systems for Treatment of Benign Prostatic Hyperplasia" and further evidence from the subsequent field evaluation study, OHTAC makes

2014 Health Technology Assessment (HTA) Database.

200. Photoselective vaporization for the treatment of benign prostatic hyperplasia

Photoselective vaporization for the treatment of benign prostatic hyperplasia Photoselective vaporization for the treatment of benign prostatic hyperplasia Photoselective vaporization for the treatment of benign prostatic hyperplasia Bowen JM, Whelan JP, Hopkins RB, Burke N, Woods EA, McIsaac GP, O'Reilly DJ, Xie F, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride J-E Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bowen JM, Whelan JP, Hopkins RB, Burke N, Woods EA, McIsaac GP, O'Reilly DJ, Xie F, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride J-E. Photoselective vaporization for the treatment of benign prostatic hyperplasia. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series (OHTAS) 13(2). 2013 Authors' conclusions For men with lower urinary tract symptoms due

2014 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>